Abstract
Nonsteriodal anti-inflammatory drugs (NSAIDs) are among the most commonly used medications in the United States and elsewhere, mainly for the treatment of arthritis. The NSAID sulindac causes regression and prevents the recurrence of premalignant colonic polyps in patients with familial adenomatous polyposis and inhibits colon carcinogenesis in rodents. Sulindac and sulindac sulfone, a metabolite of sulindac that lacks cyclooxygenase (cox) inhibitory activity, also inhibit mammary carcinogenesis in rats. To obtain insights into the relevance of these findings to human breast cancer, we examined the mechanism of action of sulindac and its sulfide and sulfone metabolites on the normal human mammary epithelial cell line MCF-10F and the human breast cancer cell line MCF-7. Of the three compounds, the sulfide was the most potent inhibitor of cell growth, although the sulfone and sulfoxide were also active at higher concentrations. Treatment of MCF-10F and MCF-7 cells with 100 µM sulindac sulfide resulted in accumulation of cells in the G1 phase of the cell cycle and induction of apoptosis. Apoptosis occurred within 24 h as determined by the TUNEL assay and DNA laddering was observed at 72 h. The accumulation of cells in G1 was associated with decreased levels of expression of cyclin D1 but no effect was seen on the expression of CDK4 or the immediate early response gene c-jun. Treatment with sulindac sulfide caused a striking induction of the CDK inhibitor p21WAF1 in MCF-10F cells. The MCF-7 cell line expressed a high basal level of p21WAF1 which did not change significantly after drug treatment. The pro-apoptotic gene BAX was not induced in either MCF-10F or MCF-7 cells by sulindac sulfide. Stable overexpression of cyclin D1, which frequently occurs in breast cancers, did not protect mammary epithelial cells from inhibition by the sulfide. These studies suggest that this class of compounds warrants further study with respect to breast cancer prevention and treatment.
Similar content being viewed by others
References
Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328: 1313–1316, 1993
Waddell WR, Ganser GF, Cerise EJ, Loughry RW: Sulindac for polyposis of the colon. Am J Surg 157: 175–179, 1989
Moorghen M, Ince P, Finney KJ, Sunter JP, Appleton DR, Watson AJ: A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol 156: 341–347, 1988
Rao CV, Rivenson A, Simi B, Zang E, Kelloff G, Steele V, Reddy BS: Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 55: 1464–1472, 1995
Thompson HJ, Briggs S, Paranka NS, Piazza GA, Brendel K, Gross PH, Sperl GJ, Pamukcu R, Ahnen DJ: Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst 87: 1259–1260, 1995
Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, Pamukcu R, Ahnen DJ: Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 57: 267–271, 1997
Shen TY, Ham EA, Cirillo VJ et al.: Prostaglandin synthetase inhibitors. In: Robinson HJ, Vane JR (eds) Prostaglandin Synthetase Inhibitors. Their Effects on Physiological Functions and Pathological States. Raven Press, New York, 1974, pp 18–31
Duggan DE, Hooke KF, Risley EA et al.: Identification of the biologically active form of sulindac. J Pharmacol Exp Ther 201: 8–13, 1977
Goldberg Y, Nassif II, Pittas A, Tsai L-L, Dynlacht BD, Rigas B, Schiff SJ: The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 12: 893–901, 1996
Piazza GA, Kulchak Rahm A, Kruntzch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS, Pamukcu R, Ahnen DJ: Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55: 3110–3116, 1995
Shiff JS, Koustos MI, Qiao L, Rigas B: Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: Effects on cell cycle and apoptosis. Exp Cell Res 222: 179–188, 1996
Shiff SJ, Qiao L, Tsai L-L, Rigas B: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenomacarcinoma cell. J Clin Invest 96: 491–503, 1995
Hunter T, Pines J: Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 79: 573–582, 1994
Sherr CJ: Mammalian G1 cyclins. Cell 79: 551–555, 1994
Gu Y, Turck CW, Morgan DO: Inhibition of cdk2 activity in vivo by an associated 20K regulatory subunit. Nature (Lond) 366: 707–710, 1993
Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR: Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211: 90–98, 1994
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature (Lond) 366: 701–704, 1993
El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Buurrell M, Hill DE, Wang Y, Wilman KG, Mercer WE, Kastan MB, Kohn KE, Elledge SJ, Kinzler KW, Vogelstein B: WAFI/CIP1is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169–1174, 1994
Calaf G, Russo J: Transformation of human breast epithelial cells by chemical carcinogens. Carcinogenesis 14: 483–492, 1995
Han EK-H, Sgambato A, Jiang W, Zhang Y-U, Santella RM, Doki Y, Cacace AM, Schieren I, Weinstein IB: Stable overexpression of cyclin D1 in a human mammary epithelial cell line prolongs the S-phase and inhibits growth. Oncogene 10: 953–961, 1995
Han EK-H, Begemann M, Sgambato A, Soh J-W, Doki Y, Xing W-Q, Liu W, Weinstein IB: Increased expression of cyclin D1 in a murine mammary epithelial line induces p27kip1, inhibits growth, and enhances apoptosis. Cell Growth Diff 7: 699–710, 1996
Sheikh MS, Rochefort H, Garcia M: Overexpression of p21WAF1/CiP1 induces growth arrest, giant cell transformation and apoptosis in human breast carcinoma cell lines. Oncogene 11: 1899–1905, 1995
Gudas J, Nguyen H, Li T, Hill D, Cowan KH: Effects of cell cycle, wild-type p53 and DNA damage on p21CIP1/Waf1 expression in human breast epithelial cells. Oncogene 11: 253–261, 1995
Tam SW, Theodoras AM, Shay JW, Draetta GF, Pagano M: Differential expression and regulation of cyclin D1protein in normal and tumor human cells: association with cdk4 is required for cyclin D1 function in G1 progression. Oncogene 9: 2663–2674, 1994
Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP: p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87: 7555–7559, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Han, E.KH., Arber, N., Yamamoto, H. et al. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat 48, 195–203 (1998). https://doi.org/10.1023/A:1005924730450
Issue Date:
DOI: https://doi.org/10.1023/A:1005924730450